Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for the treatment of Alzheimer's-related dementia
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
It signals Cordis' renewed investment in innovation
Subscribe To Our Newsletter & Stay Updated
